View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

PQG 40th Anniversary Dinner and Meeting, Milton Keynes

To celebrate its 40th anniversary, the Pharmaceutical Quality Group (PQG) is holding an anniversary dinner and a three-day meeting at the Hilton Hotel in Milton Keynes, UK.

The dinner will take place on 9 October, while the meeting will run from 9 October to 11 October.NSF’s pharma biotech team are proud to be working with the PQG and be involved in this event. It provides a fantastic agenda reflecting topical issues facing the industry today, and will be of great appeal to high-quality pharmaceutical professionals.

Day one: This day is aimed at qualified persons (QP), trainee QPs and, sponsors. Executive director of NSF’s pharma biotech team Pete Gough will present a regulatory update session and host a QP viva practice session with vice-president of NSF’s pharma biotech team John Johnson.

Day two: Director of NSF’s pharma biotech team Dave Waddington will present a serialisation update session. Day three: Pete Gough will present a legislative update session and John Johnson will present a session on best practice behaviours for perpetual good manufacturing practice (GMP) compliance.

Executive vice-president Mike Halliday and Stella Pearson-Smith will be on hand all three days to answer any questions about NSF’s QP training programme and all its other services.

You can register for the celebratory dinner and the meeting by visiting the PQG website, where you will also find a full meeting agenda.

All members and non-members are welcome to join this sharing of knowledge and experience, which also provides a fantastic networking opportunity. The NSF team looks forward to seeing you there.

Making a case for good manufacturing practice (GMP) certification of an excipient manufacturer should be a straightforward exercise since the benefits appear so clear cut...
Risk management across a global supply chain has never been a stronger factor in assuring economic success than it is now.
NSF Pharma Biotech's CEO Martin Lush recently had a meeting with a CEO to help solve his company’s pain points.
The heart of the European Union (EU) regulation of in vitro diagnostic medical devices (IVDs) lies in allowing market access to IVDs that offer clinical...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology